vinorelbine tartrate / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

58 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vinorelbine tartrate / Generic mfg.
ChiCTR-TRC-09000487: A randomized multicentre control trial of stage III non-small cell lung cancer application of concomitant radiochemotherapy

Completed
3
240
 
to receive concomitant radiochemotherapy with pemetrexed + cisplatin: pemetrexed 500mg/m2, i.v. drip d1; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week. ;to receive concomitant radiochemotherapy with vinorelbine and cisplatin: Vinorelbine 25mg/m2, i.v. drip d1, 8; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week.
Shandong Cancer Hospital; Jiangsu Hansen Pharmaceutical Co. Ltd, Shandong Provincial Scientific and Technological Project
Non-small cell lung cancer
 
 
2015-002185-23: The study is designed for patients diagnosed with a brain tumor (diffuse intrinsic pontine glioma) aged from 2 to 21 years old. Lo studio è pensato per pazienti affetti da un tumore cerebrale (glioma diffuso intrinseco del ponte) che abbiano età compresa tra 2 e 21 anni.

Not yet recruiting
3
79
Europe
Vinorelbina, Cimaher, [vinorelbina], [Cimaher], Solution for injection, Solution for infusion, NAVELBINE - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONE 1 ML, CIMAher
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", donazioni modali
diffuse intrinsic pontine glioma glioma diffuso intrinseco del ponte, children and adolescent affected by malignant glioma of the brain stem bambini e adolescenti di età superiore a 2 anni affetti da glioma maligno del tronco encefalico, Diseases [C] - Cancer [C04]
 
 
NCT00324805: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark From ECOG 1505 trial for lung cancer (adjuvant)
Feb 2016 - Feb 2016: From ECOG 1505 trial for lung cancer (adjuvant)
Checkmark Data-WCLC
More
Active, not recruiting
3
1501
Europe, Canada, US, RoW
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Onbevzi, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration, Vinorelbine Tartrate, Biovelbin, Eunades, KW 2307, KW-2307, KW2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate
National Cancer Institute (NCI), Cancer and Leukemia Group B, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
10/15
10/24
2006-003746-42: Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma

Ongoing
3
210
Europe
PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML, PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML
OSPEDALE ONCOLOGICO DI BARI
metastatic kidney carcinoma
 
 
2005-002736-10: Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer

Ongoing
3
84
Europe
Folic Acid, Gemcitabine, Vinblastine, Cisplatin, Vinorelbine, Docetaxel, Mitomycin-C, Etoposide, Vitamin B12, Carboplatin, Carboplatin
Royal Marsden Hospital
Non-small cell lung cancerSmall-cell lung cancerMalignant Mesothelioma (ICD classification code:C45.9)
 
 
2006-003503-39: Multicenter fase III undersøgelse af effekten af præoperativ (neoadjuverende) kemoterapi inden operation med efterfølgende adjuverende kemoterapi ved operabel NSCLC stadie IB, IIA; IIB, og IIIA/T3.

Ongoing
3
700
Europe
taxotere, carboplatin, cisplatin, Vinorelbine, L01CD02, L01XA02, L01X!01, Vinorelbine, taxotere, carboplatin, Cisplatin, Navirel, taxotere, carboplatin, Cisplatin, Navirel
Jens Benn Sorensen, Dept. oncology, Finsen Centre/National University Hospital
operable NSCLC.Pts are randomized to receive or not receive two courses of neoadjuvant chemotherapy before surgery
 
 
2007-002644-21: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A

Ongoing
3
864
Europe
cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta
UMCG
This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a non-inferiority design.
 
 
2016-001063-36: Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer Etude randomisée de phase III testant le nivolumab versus une chimiothérapie adaptée dans le traitement de première ligne du CBNPC chez des patients PS 2 ou de plus de 70 ans

Ongoing
3
242
Europe
nivolumab, carboplatin, pemetrexed, paclitaxel, gemcitabine, vinorelbine, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Capsule, soft, OPDIVO
CHU Rennes, Bristol-Myers Squibb
Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Diseases [C] - Cancer [C04]
 
 
ChiCTR-TRC-11001539: Recombinant endostatin (Sulijia) combined chemotherapy with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III trial

Recruiting
3
560
 
Placebo combined chemotherapy with Vinorelbine and Cisplatin (NP) ;Sulijia combined chemotherapy with Vinorelbine and Cisplatin (NP)
Cancer Institute & Hospital Chinese Academy of Medical Science; Science and Technology Department of Jiangsu Province, Jiangsu Wuzhong Pharmaceutical Group Inc.
Advanced or metastatic (IV) NSCLC
 
 
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Checkmark ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Apr 2018 - Apr 2018: ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Checkmark Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Aug 2016 - Aug 2016: Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Checkmark ARCTIC monotherapy trial for stage IIIB-IV NSCLC
More
Completed
3
597
Europe, Canada, Japan, US, RoW
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
AstraZeneca
Non - Small Cell Lung Cancer NSCLC
02/18
08/23
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
3
320
RoW
NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel
Shi Yanxia
Breast Cancer Model, Effects of Chemotherapy, Breast Cancer
03/18
03/23
NCT03359694: Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Not yet recruiting
3
300
RoW
DT group, Pegylated liposomal doxorubicin and Docetaxel, ET group, Conventional doxorubicin and Docetaxel, NX group, Navelbine and Xeloda
Tianjin Medical University Cancer Institute and Hospital
Susceptibility, Genetic, Chemotherapy Effect
11/19
10/22
IMPACT, R000007955: Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Completed
3
Japan
pemetrexed - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Shizuoka Cancer Center, AMED
Completely resected non-squamous non-small cell lung cancer patients (pathologic stage II-IIIA)
 
 
EPIC, NCT03402048: The Trial The Elderly Patient Individualized Chemotherapy Trial

Recruiting
3
567
Europe
Carboplatin, Gemcitabine, Gemzar, Pemetrexed, Alimta, Docetaxel, Taxotere, Vinorelbine, Navelbine
University of Turin, Italy
Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms
12/20
05/21
ChiCTR1900021887: A Randomized, Open, Controlled Phase III Observation of Curative Effect Clinical Study On Locally Advanced Beast Cancer Patients who Switch to GP Regimen NC After Receiving Poor Effect from TAC Regimen NC

Not yet recruiting
3
300
 
Cisplatin plus gemcitabine ;Vinorelbine bitartrate plus Cisplatin ;TAC
Affliated Tumor Hospital of Xinjiang Medical University; Affliated Tumor Hospital of Xinjiang Medical University, Self-pay
Locally advanced breast cancer
 
 
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
2021-002193-63: A Phase 3 Study of Balstilimab Compared to Chemotherapy Chosen by the Investigator in Cervical Cancer.

Not yet recruiting
3
486
Europe
Balstilimab, pemetrexed, Gemcitabine, irinotecan, Topotecan, Vinorelbine, AGEN2034, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi, Gemcitabine, Irinotecan, Topotecan, Vinorelbine
Agenus, Inc., Agenus, Inc.
recurrent, persistent, or metastatic cervical cancer that have progressed after receiving platinum-based chemotherapy, Cancer that develops in a woman's cervix, Diseases [C] - Cancer [C04]
 
 
NCT02974426: To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Terminated
3
132
RoW
PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Shanghai Chest Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
02/24
02/24
JIPANG, R000007398: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)

Completed
3
230
Japan
gefitinib - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Suita Tokushukai Hospital, AstraZeneca K.K.
Resected pathological stage II or III non-small cell lung cancer with mutated EGFR
 
 
2020-005620-12: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer Ensayo clínico de Dato-DXd en comparación con la quimioterapia de elección del investigador en cáncer de mama inoperable o metastásico, con receptores hormonales positivos HER2 negativo.

Not yet recruiting
3
700
Europe
Datopotamab deruxtecan, Eribulin mesylate, Capecitabine, Gemcitabine, Vinorelbine, DS-1062a, Powder for concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Powder for solution for infusion, HALAVEN, Capecitabine Accord, Bendacitabin, Bendarelbin
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Cáncer de mama inoperable o metastásico, con receptores hormonales positivos, HER2 negativo, tratado una o dos líneas previas de quimioterapia sistémica, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
ChiCTR2300072390: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive breast cancer

Completed
3
570
 
HS022+Vinorelbine ;Trastuzumab +vinorelbine for injection
Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University); Haizheng Pharmaceutical (Hangzhou) Co., Ltd, Sponsor
Breast cancer
 
 
NCT06107790: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Completed
3
570
RoW
HS022, Trastuzumab, Vinorelbine Bitartrate
Zhejiang Hisun Pharmaceutical Co. Ltd.
HER2-positive Breast Cancer
01/22
01/22
NCT04665986: Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Not yet recruiting
3
50
NA
Navelbine, Docetaxel
Zhejiang Cancer Hospital
Breast Cancer
02/22
02/23
IPSOS, NCT03191786 / 2015-004105-16: A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Checkmark Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Completed
3
453
Europe, Canada, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, MPDL3280A, Vinorelbine, Navelbine®, Gemcitabine, Gemzar®
Hoffmann-La Roche
Non-Small Cell Lung Cancer
04/22
10/23
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
NCT03381066: A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Recruiting
3
225
RoW
gefitinib, pemetrexed,cisplatin, Intercalating arm, Vinorelbine, cisplatin, chemotherapy alone arm
Yonsei University
Completely Resected NSCLC With Common EGFR Mutations
12/22
12/22
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Terminated
3
1
RoW
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer
01/22
12/22
ARST1431, NCT02567435: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Active, not recruiting
3
325
Canada, US, RoW
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
06/23
10/24
NCT02465736: Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Active, not recruiting
3
610
RoW
Docetaxel, Docetaxel in Arm A, Cisplatin, Cisplatin in Arm A, Radiation, IMRT, Surgery, Esophagectomy, Vinorelbine, Vinorelbine in Arm B, Cisplatin in Arm B
Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer
07/25
07/25
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT06143553: Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Recruiting
3
168
RoW
Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)
Shanghai Yizhong Pharmaceutical Co., Ltd.
Metastatic Breast Cancer (MBC)
07/25
07/25
OptiTROP-Breast01, NCT05347134: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting
3
254
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
10/23
12/24
ChiCTR1900021218: Vinorelbine soft capsule and capecitabine as maintenance therapy for advanced triple negative breast cancer after first-line chemotherapy: a randomized, open, non inferiority phase III clinical study

Recruiting
3
186
 
Capecitabine ;Vinorelbine
Sun Yat-sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Sun Yat-sen Memorial Hospital Yat-sen Clinical Research and Cultivation Project
Breast cancer
 
 
B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting
3
302
RoW
Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven
Sun Yat-sen University
Breast Cancer, Refractory Breast Carcinoma
02/26
01/28
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Recruiting
3
382
RoW
BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HR+HER2- Breast Cancer
05/26
05/26
ALINA, NCT03456076 / 2017-004331-37: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
257
Europe, Japan, US, RoW
Alectnib, RO5424802, Cisplatin, Vinorelbine, Navelbine, Gemcitabine, Gitrabin, Pemetrexed, Alimta®, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
06/23
11/26
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Recruiting
3
406
RoW
BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
06/26
06/26
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Shanghai Escugen Biotechnology Co., Ltd
Metastatic Breast Cancer
07/26
12/26
ENGOT-cx20, NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/)

Recruiting
3
686
Europe, US, RoW
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
3
350
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
08/26
06/27
JZP598-303, NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting
3
550
US
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Jazz Pharmaceuticals
Metastatic HER2-positive Breast Cancer
09/28
11/31
IMpower010, NCT02486718 / 2014-003205-15: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer []

Checkmark Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Aug 2022 - Aug 2022: Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Checkmark Data from IMpower010 trial for stage IB-IIIA NSCLC
Aug 2022 - Aug 2022: Data from IMpower010 trial for stage IB-IIIA NSCLC
Checkmark Approval for adjuvant NSCLC based on IMpower010
More
Active, not recruiting
3
1280
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A; TECENTRIQ, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Hoffmann-La Roche
Non-Small Cell Lung Cancer
01/24
08/35
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Checkmark Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at SABCS 2022
Checkmark Post hoc subgroup analysis from P3 TROPiCS-02 study in HR+ve, HER2-ve mBC at ESMO 2022
Sep 2022 - Sep 2022: Post hoc subgroup analysis from P3 TROPiCS-02 study in HR+ve, HER2-ve mBC at ESMO 2022
Checkmark Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at ESMO 2022
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
TROPION-Lung12, NCT06564844: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Not yet recruiting
3
660
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, DS-1062a, Rilvegostomig, AZD2936, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
AstraZeneca, Daiichi Sankyo
Non-small Cell Lung Cancer
11/31
02/35
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
TROPION-Breast01, NCT05104866 / 2020-005620-12: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

Calendar Jan 2024 - Dec 2024: Data from TROPION-Breast01 trial for inoperable or metastatic HR+, HER2- breast cancer
Hourglass Feb 2024 - Mar 2024 : Q4 FY'23 - Acceptance of regulatory submission in US for 2-3L HR+, HER2- breast cancer (based on TROPION-Breast01 trial)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Capecitabine, Gemcitabine, Eribulin, Eribulin Mesylate, Vinorelbine
AstraZeneca, Daiichi Sankyo
Breast Cancer
07/24
08/25
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
3
192
RoW
VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC
Fudan University
Triple-Negative Breast Cancer
08/25
02/26
NCT03203590: Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Not yet recruiting
3
590
RoW
Oral Navelbine + Carboplatin, Vinorelbine, Carboplat, Gefitinib, Iressa
Sun Yat-sen University, Shenzhen People's Hospital, Dongguan People's Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Maoming Affiliated Hospital of Southern Medical University
2-year Disease-Free Survival
01/26
01/26
SYSA1501-007, NCT05901935: DP303c in Patients With HER2-positive Advanced Breast Cancer

Not yet recruiting
3
420
NA
DP303c, Trastuzumab, Vinorelbine Tartrate, Capecitabine tablets
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-positive Advanced Breast Cancer
01/26
07/28
SKB264-Ⅲ-10, NCT06081959: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
376
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Metastatic Breast Cancer
03/26
12/27
ALPHABET, NCT05063786 / 2020-005639-65: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer

Active, not recruiting
3
27
Europe
Trastuzumab, Herceptin, Alpelisib, Piqray, Fulvestrant, Faslodex, Vinorelbine, Navelbine, Capecitabine, Xeloda, Eribulin, Halaven
Spanish Breast Cancer Research Group, ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals
Advanced Breast Cancer
11/24
11/24
LungMate-008, NCT04772287: Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC

Not yet recruiting
3
341
NA
Toripalimab, Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel, Toripalimab mimetic (placebo)
Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
12/26
12/27
NCT05711628: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn
3
334
NA
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Bendamustine, SDX-105, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Transplant Conditioning, conditioning regimen, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/28
06/28
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Not yet recruiting
3
632
NA
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
10/28
10/31

Download Options